Aptevo Therapeutics Inc (NASDAQ:APVO) SVP Randy Joe Maddux acquired 5,000 shares of the company’s stock in a transaction on Thursday, December 6th. The shares were purchased at an average cost of $2.37 per share, for a total transaction of $11,850.00. Following the acquisition, the senior vice president now owns 30,000 shares of the company’s stock, valued at approximately $71,100. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of APVO traded down $0.06 during mid-day trading on Friday, hitting $2.20. 41,500 shares of the company’s stock were exchanged, compared to its average volume of 75,120. Aptevo Therapeutics Inc has a fifty-two week low of $2.10 and a fifty-two week high of $6.35. The company has a market capitalization of $51.28 million, a price-to-earnings ratio of -1.44 and a beta of 2.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.65 and a current ratio of 3.91.
Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.01. Aptevo Therapeutics had a negative net margin of 252.44% and a negative return on equity of 78.85%. The business had revenue of $5.82 million during the quarter, compared to the consensus estimate of $6.87 million. Equities research analysts forecast that Aptevo Therapeutics Inc will post -2.31 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aptevo Therapeutics during the second quarter worth about $148,000. Northern Trust Corp boosted its stake in shares of Aptevo Therapeutics by 21.2% during the second quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock worth $352,000 after buying an additional 12,299 shares during the period. EAM Investors LLC acquired a new stake in shares of Aptevo Therapeutics during the second quarter worth about $552,000. Acadian Asset Management LLC boosted its stake in shares of Aptevo Therapeutics by 20.2% during the third quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock worth $2,244,000 after buying an additional 74,256 shares during the period. Finally, Sessa Capital IM L.P. boosted its stake in shares of Aptevo Therapeutics by 35.9% during the third quarter. Sessa Capital IM L.P. now owns 706,613 shares of the biotechnology company’s stock worth $3,590,000 after buying an additional 186,719 shares during the period. Institutional investors and hedge funds own 32.77% of the company’s stock.
Several equities analysts have issued reports on APVO shares. Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Tuesday, August 14th. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 13th. Roth Capital set a $12.00 price objective on Aptevo Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 15th. LADENBURG THALM/SH SH started coverage on Aptevo Therapeutics in a report on Monday, November 5th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Aptevo Therapeutics in a report on Friday, August 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aptevo Therapeutics has an average rating of “Buy” and a consensus price target of $10.69.
TRADEMARK VIOLATION WARNING: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2018/12/08/insider-buying-aptevo-therapeutics-inc-apvo-svp-acquires-5000-shares-of-stock.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.